D.E. Shaw & Co’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,367,343
| Closed | -$4.16M | – | 4876 |
|
|
2024
Q4 | $4.16M | Sell |
1,367,343
-564,862
| -29% | -$2.46M | ﹤0.01% | 2126 |
|
|
2024
Q3 | $10M | Buy |
1,932,205
+1,824,225
| +1,689% | +$9.07M | 0.01% | 1429 |
|
|
2024
Q2 | $278K | Sell |
107,980
-190,130
| -64% | -$649K | ﹤0.01% | 3937 |
|
|
2024
Q1 | $1.47M | Sell |
298,110
-113,640
| -28% | -$673K | ﹤0.01% | 2846 |
|
|
2023
Q4 | $3.62M | Sell |
411,750
-370,266
| -47% | -$3.03M | ﹤0.01% | 2179 |
|
|
2023
Q3 | $8.97M | Sell |
782,016
-1,229,653
| -61% | -$23.6M | 0.01% | 1362 |
|
|
2023
Q2 | $50.9M | Sell |
2,011,669
-280,242
| -12% | -$8.73M | 0.05% | 425 |
|
|
2023
Q1 | $73.8M | Buy |
2,291,911
+952,991
| +71% | +$29.7M | 0.08% | 301 |
|
|
2022
Q4 | $24.7M | Sell |
1,338,920
-130,653
| -9% | -$2.99M | 0.03% | 789 |
|
|
2022
Q3 | $39.7M | Buy |
1,469,573
+651,833
| +80% | +$13.2M | 0.05% | 486 |
|
|
2022
Q2 | $11.3M | Sell |
817,740
-28,528
| -3% | -$439K | 0.01% | 1288 |
|
|
2022
Q1 | $16.5M | Buy |
846,268
+322,350
| +62% | +$4.89M | 0.02% | 1169 |
|
|
2021
Q4 | $8.55M | Buy |
523,918
+514,678
| +5,570% | +$8.58M | 0.01% | 1815 |
|
|
2021
Q3 | $257K | Sell |
9,240
-38,847
| -81% | -$1.11M | ﹤0.01% | 4445 |
|
|
2021
Q2 | $1.43M | Buy |
+48,087
| New | +$1.39M | ﹤0.01% | 3257 |
|
|
2021
Q1 | – | Sell |
-8,933
| Closed | -$253K | – | 4565 |
|
|
2020
Q4 | $253K | Sell |
8,933
-22,651
| -72% | -$587K | ﹤0.01% | 3652 |
|
|
2020
Q3 | $794K | Buy |
31,584
+20,473
| +184% | +$537K | ﹤0.01% | 2985 |
|
|
2020
Q2 | $271K | Sell |
11,111
-1,189
| -10% | -$23.5K | ﹤0.01% | 3665 |
|
|
2020
Q1 | $182K | Buy |
+12,300
| New | +$254K | ﹤0.01% | 3676 |
|
|
2019
Q3 | – | Sell |
-21,686
| Closed | -$281K | – | 4063 |
|
|
2019
Q2 | $281K | Sell |
21,686
-8,043
| -27% | -$101K | ﹤0.01% | 3342 |
|
|
2019
Q1 | $469K | Sell |
29,729
-70,761
| -70% | -$1.23M | ﹤0.01% | 3026 |
|
|
2018
Q4 | $2.02M | Buy |
100,490
+35,288
| +54% | +$778K | ﹤0.01% | 2137 |
|
|
2018
Q3 | $1.62M | Sell |
65,202
-12,792
| -16% | -$348K | ﹤0.01% | 2350 |
|
|
2018
Q2 | $2.14M | Buy |
77,994
+68,706
| +740% | +$2.06M | ﹤0.01% | 2176 |
|
|
2018
Q1 | $286K | Sell |
9,288
-34,884
| -79% | -$1.12M | ﹤0.01% | 3169 |
|
|
2017
Q4 | $1.58M | Buy |
+44,172
| New | +$1.27M | ﹤0.01% | 2305 |
|
|
2017
Q1 | – | Sell |
-10,717
| Closed | -$222K | – | 3655 |
|
|
2016
Q4 | $222K | Buy |
+10,717
| New | +$179K | ﹤0.01% | 3236 |
|
|
2016
Q2 | – | Sell |
-54,621
| Closed | -$954K | – | 3575 |
|
|
2016
Q1 | $954K | Sell |
54,621
-105,318
| -66% | -$2.14M | ﹤0.01% | 2384 |
|
|
2015
Q4 | $5.46M | Buy |
159,939
+134,539
| +530% | +$4.66M | 0.01% | 1345 |
|
|
2015
Q3 | $756K | Sell |
25,400
-16,372
| -39% | -$497K | ﹤0.01% | 2796 |
|
|
2015
Q2 | $1.34M | Buy |
+41,772
| New | +$1.07M | ﹤0.01% | 2493 |
|
Other funds holding RVNC
D.E. Shaw & Co's RVNC Position: Q1 2025 in Review
D.E. Shaw & Co sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 1,367,343 shares — an estimated $4.16M sold.
D.E. Shaw & Co first reported a position in RVNC in Q2 2015 and held it in 31 quarters. The position peaked at $73.8M in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- D.E. Shaw & Co reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- D.E. Shaw & Co sold 1,367,343 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $4.16M.
- D.E. Shaw & Co first reported a position in Revance Therapeutics, Inc. in Q2 2015 and held it in 31 quarters.
- D.E. Shaw & Co's Revance Therapeutics, Inc. position peaked at $73.8M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on D.E. Shaw & Co's 13F filing for Q1 2025, filed 15 May 2025.